Dr. Sledge on Using PCR To Determine Therapy Benefit for Breast Cancer

George W. Sledge, Jr., MD
Published: Tuesday, Mar 24, 2015



George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine discusses the benefits of using pathological complete response rate (PCR) to understand therapy benefit in breast cancer.
 
Approvals for adjuvant therapy for patients with early stage breast cancer are typically based on large randomized trials, says Sledge. However, this is not always the most effective method to find treatment options, as these trials tend to be costly and take a long time to determine if patients are receiving clinical benefit.
 
Using neoadjuvant therapy to look at PCR offer an alternative. PCR can act as a surrogate to determine long-term benefit for disease-free survival and overall survival, explains Sledge.


George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine discusses the benefits of using pathological complete response rate (PCR) to understand therapy benefit in breast cancer.
 
Approvals for adjuvant therapy for patients with early stage breast cancer are typically based on large randomized trials, says Sledge. However, this is not always the most effective method to find treatment options, as these trials tend to be costly and take a long time to determine if patients are receiving clinical benefit.
 
Using neoadjuvant therapy to look at PCR offer an alternative. PCR can act as a surrogate to determine long-term benefit for disease-free survival and overall survival, explains Sledge.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x